A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

Please provide your email address to receive an email when new articles are posted on . In patients having TAVR, cerebral embolic protection reduced risk for periprocedural stroke in patients from the ...

- TRUFILL n-BCA is now indicated for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and Chronic Subdural Hematoma (cSDH) as an adjunct to surgery. - ...

The global TAVR embolic protection market is experiencing steady growth, with revenue estimated to increase from approximately $124 million in 2023 to around $403 million by 2032. This growth, driven ...

SANTA CRUZ, Calif., May 9, 2023 /PRNewswire/ -- Emboline, Inc., a privately held medical technology company focused on reducing stroke during structural heart procedures such as transcatheter aortic ...

NEW YORK, NY—Use of a cerebral embolic protection device (EPD) during TAVI may prevent disabling strokes, but any effect appears to be modest, according to an updated analysis of the Society of ...